Immunovia
1.738 SEK +6.23%Be the first to follow this company
Immunovia is a biotechnology company. The company's research and development is focused on molecular diagnostics, where the business focuses on driving the development and change of current working methods for diagnosing complex cancers and immune diseases. The vision is to establish blood-based tests to be able to identify different types of pancreatic cancer at an early stage. The company was founded in 2007 and is headquartered in Lund.
Revenue
1.58M
EBIT %
-18,763.29 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
IMMNOV
Daily low / high price
1.666 / 1.868
SEK
Market cap
78.71M SEK
Turnover
851.59K SEK
Volume
495K
Financial calendar
Interim report
2024-08-22
Interim report
2024-11-14
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Försäkringsbolaget Avanza Pension | 9.9 % | 9.9 % |
Carl Borrebaeck | 3.8 % | 3.8 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Immunovia AB: Immunovia's new lab staffed and operational after rapid implementation
Immunovia AB: BULLETIN FROM THE ANNUAL GENERAL MEETING ON 19 JUNE 2024 IN IMMUNOVIA AB (PUBL)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools